Drug Trial Radar · NCT00515554
HD18 for Advanced Stages in Hodgkins Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,500
Actual
Start
May 2008
Primary completion
Jul 2019
Study completion Jul 2020
Sponsor
- Lead sponsor
- University of CologneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 13, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to test: 1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) 2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.
Conditions
- Hodgkins Lymphoma
Interventions
RituximabDrug
addition of Rituximab to BEACOPP escalated
BEACOPP escalatedDrug
chemotherapy with BEACOPP escalated
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.